These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8553904)

  • 1. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
    Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò MG
    J Biol Regul Homeost Agents; 1995; 9(1):21-3. PubMed ID: 8553904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relation between macrophage and T helper-2 lymphocyte functions in human neoplasms: neopterin, interleukin-10 and interleukin-6 blood levels in early or advanced solid tumors.
    Lissoni P; Rovelli F; Tisi E; Brivio F; Ardizzoia A; Barni S; Tancini G; Saudelli M; Cesana E; Viganò MG
    J Biol Regul Homeost Agents; 1995; 9(4):146-9. PubMed ID: 8844339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
    Lissoni P; Tisi E; Brivio F; Ardizzoia A; Crispino S; Barni S; Tancini G; Conti A; Maestroni GJ
    J Biol Regul Homeost Agents; 1991; 5(4):154-6. PubMed ID: 1803863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
    Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
    J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of interactions among markers of macrophage functions in metastatic solid tumors: neopterin levels in relation to those of tumor necrosis factor-alpha and of soluble interleukin-2 receptors.
    Lissoni P; Brivio F; Fumagalli L; Galimberti C; Cataldo M; Marsili MT; Brivio O; Barni S; Tancini G; Angelini A
    J Biol Regul Homeost Agents; 1994; 8(1):32-5. PubMed ID: 7976492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
    Lissoni P; Brivio F; Viviani S; Fumagalli L
    J Biol Regul Homeost Agents; 1999; 13(2):110-4. PubMed ID: 10503734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of granulocyte-macrophage colony stimulating factor on soluble interleukin-2 receptor serum levels and their relation to neopterin and tumor necrosis factor-alpha in cancer patients.
    Crispino S; Lissoni P; Ardizzoia A; Rovelli F; Perego MS; Grassi MG; Barni S; Pittalis S; Tancini G
    J Biol Regul Homeost Agents; 1993; 7(3):92-4. PubMed ID: 8135145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of IL-2 immunotherapy in metastatic renal cell carcinoma in relation to the psychic profile as evaluated using the Rorschach test.
    Messina G; Lissoni P; Bartolacelli E; Fumagalli L; Brivio F; Colombo E; Gardani GS
    Anticancer Res; 2007; 27(4C):2985-8. PubMed ID: 17695482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
    Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
    J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mononuclear cell activation in Crohn's disease. Evaluation using serum assay of neopterin and interleukin-2 soluble receptors].
    Duclos B; Reimund JM; Lang JM; Coumaros G; Chamouard P; Lehr L; Baumann R; Koehl C; Weill JP
    Gastroenterol Clin Biol; 1990; 14(1):22-7. PubMed ID: 2311849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2.
    Di Felice G; Fumagalli L; Majorca F; Barni S; Ardizzoia A; Tancini G; Lissoni P
    J Biol Regul Homeost Agents; 1996; 10(4):98-9. PubMed ID: 9604779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increase in soluble interleukin-2 receptor and neopterin serum levels during immunotherapy of cancer with interleukin-2.
    Lissoni P; Tisi E; Brivio F; Barni S; Rovelli F; Perego M; Tancini G
    Eur J Cancer; 1991; 27(8):1014-6. PubMed ID: 1832885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
    Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
    Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
    Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
    Zhang GJ; Adachi I
    Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: effects of chlorambucil.
    Clements PJ; Peter JB; Agopian MS; Telian NS; Furst DE
    J Rheumatol; 1990 Jul; 17(7):908-10. PubMed ID: 2213757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune and endocrine mechanisms of advanced cancer-related hypercortisolemia.
    Lissoni P; Brivio F; Fumagalli L; Messina G; Secreto G; Romelli B; Fumagalli G; Rovelli F; Colciago M; Brera G
    In Vivo; 2007; 21(4):647-50. PubMed ID: 17708360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of erythrosedimentation rate in cancer in relation to cytokine production: correlation with high IL-6 and low IL-2 blood concentrations.
    Lissoni P; Brivio F; Pittalis S; Rovelli F; Rescaldani R; Perego MS; Grassi MG; Barni S; Tancini G; Majorca F; Fumagalli L
    J Biol Regul Homeost Agents; 1996; 10(2-3):60-2. PubMed ID: 9250887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neopterin in renal cell carcinoma: inhalational administration of interleukin-2 is not accompanied by a rise of urinary neopterin.
    Melichar B; Solichová D; Svobodová I; Melicharová K
    Luminescence; 2005; 20(4-5):311-4. PubMed ID: 16134219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of macrophage response to interleukin-2 immunotherapy by interleukin-3 in cancer patients.
    Lissoni P; Rovelli F; Barni S; Ardizzoia A; Pittalis S; Tisi E; Perlangeli V; Tancini G
    Biol Chem Hoppe Seyler; 1992 Dec; 373(12):1217-22. PubMed ID: 1292506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.